Tilray Stock Plummets Amid ‘Buy the News’ Reaction to Rescheduling
Tilray Brands experienced a significant downturn in its stock value on Wednesday, with shares plummeting 9% during the afternoon trading session. This decline stemmed from a ‘buy the rumor, sell the news’ reaction following a pivotal announcement regarding the U.S. government’s intentions to reschedule cannabis. President Donald Trump had issued an executive order directing federal agencies to reclassify cannabis, moving it from Schedule I to Schedule III – a less restrictive category – marking a key step in the industry’s long-standing efforts to gain federal recognition and legitimacy. Despite the anticipated positive impact of this development, investors reacted with a swift sell-off, seemingly anticipating a more comprehensive shift in policy. The stock closed the day at $11.15, a substantial drop from its previous close, reflecting the market’s immediate response to the news.
The U.S. government’s rescheduling decision represents a critical change in the regulatory landscape surrounding cannabis. Moving cannabis to Schedule III – alongside drugs like dextromethorphan and oxymethazoline – acknowledges the substance’s potential for abuse but designates it as having a substantially lower abuse potential than Schedule I drugs, such as heroin or LSD. This shift is a symbolic victory for the cannabis industry, which has long argued that its products should be treated with a more nuanced approach, recognizing their potential medical applications and acknowledging the existing, largely unregulated, market. However, the move alone does not legalize recreational cannabis use or substantially alter the legal framework governing its production and sale. Investors’ reaction underscores the anticipation for further, more transformative policy changes, which, as of Wednesday’s close, had not materialized.
Tilray Brands’ stock has demonstrated considerable volatility over the past year, exhibiting a pattern of significant price swings. Specifically, the company’s shares have undergone 93 distinct movements exceeding a 5% change in value within the last 12 months. This high degree of volatility is exemplified by Wednesday’s dramatic decline, which followed a previous 5.2% drop announced two days prior. That earlier downturn was triggered by news that the administration was actively considering a similar rescheduling effort, leading to a prior rally of roughly 27% the day before. The market’s reaction highlights the sensitivity of the stock to news surrounding cannabis policy and regulatory changes. It also reflects a common investor behavior – taking profits after a rapid, speculative increase.
Tilray Brands’ stock had already experienced a remarkable climb, increasing nearly 75% over the preceding five trading days, fueled by the speculation of a rescheduling announcement. This surge underscores the market’s eagerness to react to any perceived progress in federal cannabis policy. The initial excitement was based on reports that the administration was actively weighing a shift in the drug’s classification, viewing it as a less dangerous substance, a perspective directly linked to reducing the risk associated with cannabis use. This anticipation created a self-fulfilling prophecy, driving the stock price upward before the actual announcement.
As of the close on Wednesday, Tilray Brands’ stock had fallen 23.9% since the beginning of the year. Trading at $11.12 per share, it was currently 47.1% below its 52-week high of $21, which was established in October 2025. These figures provide a tangible illustration of the recent stock performance. The company’s financial standing, reflected in these metrics, represents a significant deviation from its peak value. The significant drop underscores the challenges the company faces in translating policy-related optimism into sustainable long-term growth.
The market’s reaction to the rescheduling announcement, while immediate and dramatic, highlights the complex dynamics surrounding the future of cannabis within the United States. While this government action represents a critical step towards greater recognition, it does not represent a complete overhaul of cannabis regulations. Moving to Schedule III positions cannabis as a drug with a lower abuse potential, but it still carries legal restrictions. Investors will now keenly monitor subsequent developments, including any further policy shifts or legislative actions that could fundamentally alter the landscape for cannabis companies like Tilray Brands. The ongoing evolution of U.S. cannabis policy will continue to heavily influence the market’s perception and valuation of the industry’s leading players.
